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Abstract The development of personalised medicine is of
considerable importance for paediatric patient populations,
and represents a move away from the use of treatment
dosages based on experience with the same compounds in
adults. Currently, however, we know little about develop-
mental pharmacogenomics and, although many biomarkers
are available for clinical research use, there have been few
applications in the management of paediatric diseases. This
paper reviews where we are in the journey towards
achieving paediatric personalised medicine and describes a
group of diseases requiring such an approach. The
personalised medicine approach is particularly relevant for
the treatment of rare childhood diseases, and the group of
life-threatening neurological disorders known as lysosomal
storage diseases represents a potential study population.
The genetic bases of these disorders are generally well
defined, there is the potential for diagnosis at birth or
prenatally, and there are a range of therapeutic options
available or under development.
Keywords Paediatric population . Neurological
impairment . Rare disease . Biomarker . Pharmacogenomic .
Personalised medicine
Introduction
Today, clinical research is strongly regulated with the aim
of ensuring that clinical trials are well designed and
conducted in an ethical manner. In Europe, several guide-
lines, directives and regulations pertaining to clinical trials
have been released by the European Parliament, Council
and Commission [1–3]. One in particular, Directive 2001/
20/EC, establishes specific provisions regarding the con-
duct of clinical trials of medicinal products on human
subjects and recognises the principles of good clinical
practice [1]. In line with this, many medicines have
been developed based on the results of well-designed,
randomised, controlled clinical trials, and these treatments
are currently used in a range of patient groups, offering
considerable clinical and economic utility in healthcare.
That said, however, it is widely acknowledged that not all
patients respond in the same way to a given therapy and, as
a result, the current methodological approach will require
updating in future to take account of individual patient
characteristics.
For many adult and some childhood conditions, bio-
markers that reliably reflect inter-individual variability in
disease expression and that also correlate with or predict
outcomes have already been discovered among the genes,
mRNA, proteins and metabolites found in the body.
Polymorphisms in the human leukocyte antigen (HLA),
for example, have been identified as risk factors for severe
adverse drug reactions (ADRs): these include the associa-
tion between HLA-B*1502 and carbamazepine-induced
skin necrolysis and Stevens–Johnson syndrome [4], as well
as the association between HLA-B*5701 and hypersensi-
tivity reactions to the HIV drug, abacavir [5, 6]. Screening
for both of these alleles is recommended before starting the
respective treatment and, in the case of HLA-B*5701,
M. Scarpa (*) : R. Tomanin




A. Ceci : P. Mincarone





EPMA Journal (2011) 2:231–239
DOI 10.1007/s13167-011-0081-2
screening prior to abacavir initiation has been suggested to
produce cost savings [6, 7]. In future, it is expected that
such biomarkers will be detected more readily thanks to the
new high-throughput technologies and powerful analytical
approaches employed within the fields of pharmacogenom-
ics, proteomics, metabolomics and other so-called ‘omics’.
This type of genetic knowledge may ultimately be
included within the drug development process where
biomarkers will serve as identifiers of treatment response.
As a result, it will become important to include population
screening early in the clinical trial development phase in
order to establish which subpopulations receiving an
experimental drug are most/least likely to benefit from, or
to experience adverse reactions associated with, that
treatment. Refinement of this approach will lead to more
targeted patient recruitment and should reduce the likeli-
hood of new therapies failing at the clinical trial stage. Most
importantly, it should reduce the risk of unsuccessful
treatments or undesired secondary adverse effects in clinical
practice. Whether pharmacodiagnostic (theranostic) appli-
cations can simplify the selection of drugs for clinical
testing, and help to develop more focused clinical trials
that provide enhanced knowledge about the effects of a
drug in humans within shorter time frames, are currently
being explored by various organisations such as the
National Institutes of Health (NIH) [8].
The use of biomarkers in paediatrics
The use of biomarkers as indicators of genetic factors
affecting drug response is of particular interest for children.
Historically, despite the need for treatments for conditions
affecting children, for ethical, economic and methodolog-
ical reasons, there have been few clinical trials in young
populations [9, 10]. As a result, off-label drug use in
paediatric patients has been relatively common [9, 11, 12].
An example of this is the fact that metabolic capacity is
different in children and adults. Hepatic glucoronidation
activity of the UDP-glucuronosyltransferase (UGT) family
of enzymes that are needed for the elimination of certain
xenobiotic and endogenous substances, for instance, is
lower in children than adults which may have implications
for drug detoxification [13]. UGT activity towards bilirubin
at birth, for example, is approximately 1% of the level
observed in adults [14], although activity increases rapidly
and reaches levels equivalent to those in adults 14 weeks
after birth [15]. Total UGT activity has been reported to
develop to adult levels by 20 months of age; however, that
age at which enzymes reach adult levels of activity may not
be universally indicative of in vivo drug clearance [16].
This study showed that intrinsic hepatic clearance of the
antipsychotic drug trifluoperazine did not appear to reach
adult levels until 18.9 years of age despite UGT being
maximally active well before this time. These types of
infancy/childhood-specific developmental changes are
clearly complex and likely underlie some of the variability
in drug response seen in neonates and children. Failing to
take the potential impact of these differences on drug action
into account places children at risk of ADRs.
In recent years there has in fact been a rise in the number
of paediatric drug safety and efficacy studies, as well as
changes in drug labelling for young patients that show
unique paediatric doses are often necessary [17, 18].
Furthermore, some diseases that occur in children either
do not develop in adults or have a different effect/
prevalence in adults, making it necessary to develop drugs
specifically for children. Despite the clear need for
individualised medicine for paediatric patient populations,
we still know very little about developmental pharmacoge-
nomics and there have been few applications of biomarkers
in the management of paediatric disease [19]. Results of a
literature search conducted by the Task force in Europe for
Drug Development for the Young (TEDDY) European
Network of Excellence demonstrated that throughout the
world more than 50% of pharmacogenomic/pharmacoge-
netic research activities in children during the last 10 years
were related to predisposition, which means the investiga-
tion of the correlation between genetic traits and the
probability of or susceptibility for a given pathology or
disease [20]. These types of exploratory studies provide
little or no insight into mechanisms of disease or drug
action, and their results cannot be used to improve medical
practice or to support therapeutic solutions. Only a small
number of polymorphisms that are linked to therapeutic
response have been studied in children and, even when
studies demonstrate an impact on treatment response, their
use in clinical practice remains limited. This is highlighted
by the fact that very few FDA drug label amendments for
pharmacogenomic testing refer to paediatric populations
[9].
A major consideration that has arisen from analyses of
publications on pharmacogenetics and pharmacogenomics
is that studies often show contradictory or inconsistent
results. This is particularly the case for studies in paediatric
populations which, by definition, generally have limited
patient numbers. A systematic review and field synopsis of
pharmacogenetic studies in general that was conducted in
2009 suggested that the limited translation of pharmacoge-
netic research into practice may be explained by the
preponderance of reviews over primary research, small
sample sizes, a mainly candidate gene approach, the use of
surrogate markers, an excess of nominally positive or truly
positive associations and paucity of meta-analyses [21].
The small sample sizes, coupled with the more frequent
evaluation of common rather than rare variants, the use of
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surrogate outcome measures rather than more clinically
relevant outcomes, and subgroup analysis with multiple
hypothesis testing, suggest that only a proportion of the
positive associations reported are in fact genuine [21]. Clear
analysis of the situation is further complicated by the use of
different research methods across studies, the lack of both
standardised outcome measures and study replication, and
the low level of consideration given to potential covariates
such as co-morbidities. Other investigators have similarly
raised concerns about the need to improve the quality of
studies and prevent false-positive associations [19]. In
conclusion, while the new ‘omics’ techniques offer great
promise for the identification of biomarkers of drug
response, these studies are subject to many of the same
pitfalls that apply in general to paediatric and other clinical
trials.
Notwithstanding the limited experience and considera-
tions above, some exciting examples of the usefulness of
biomarkers in clinical practice can be derived from recent
published literature. Childhood disorders in which pharma-
cogenetic studies have most commonly been conducted
include acute lymphoblastic leukaemia, attention–deficit
hyperactivity disorder, growth hormone deficiency, juvenile
idiopathic arthritis, atopic dermatitis and asthma (see [19,
22, 23] for reviews). A good example of a childhood
condition where there will be benefits from the use of
pharmacogenetics is acute lymphoblastic leukaemia (ALL).
Current treatment for patients with ALL results in event-
free survival greater than 75% for most patients; however,
approximately 25% fail to respond to treatment [24]. One
of the reasons for treatment failure is the development of
toxicity due to the absence or presence of only low levels of
enzymes that metabolise chemotherapies. Thiopurines
(azathioprine, mercaptopurine and thioguanine), for exam-
ple, are often used to treat ALL and their safety has been
shown to be related to thiopurine methyltransferase
(TPMT) genotype. Genotypes resulting in reduced TPMT
enzyme activity have been shown to be associated with
dose-related side effects/toxic events to thiopurines in children
with ALL [25–27]. Thus, TPMT genotype may be used to
help choose the appropriate dose of thiopurine for an
individual child. In the US, the drug labels for azathioprine
and 6-mercaptopurine now give the FDA recommendation
for TPMT testing [9]. Although this biomarker is not yet
reliably assessed in children within Europe, because TPMT-
deficiency can now be easily detected, this knowledge
should lead to improvements in the safety of treatment in
children receiving thiopurine chemotherapy. The recent
publication of Clinical Pharmacogenetics Implementation
Consortium Guidelines for TPMT genotyping and thiopurine
dosing may also facilitate the routine incorporation of TPMT
genotyping in clinical practice for paediatric patients
receiving these compounds [28].
What is available and what is needed to develop
personalised medicines?
There are several pharmacogenomic/pharmacogenetic net-
works already in existence that aim to help collect,
coordinate or communicate information about genetic
determinants of drug response. In Europe, for example,
there is the European Network for Pharmacogenetics
(http://www.epr-network.org/), in the US there is the NIH
Pharmacogenomics Research Network (http://www.nigms.
nih.gov/Initiatives/PGRN), in Canada, the Canadian Phar-
macogenomics Network for Drug Safety (CPNDS), and
there is also the International HapMap project (http://
hapmap.ncbi.nlm.nih.gov/) that represents a partnership of
researchers and funding agencies from several countries.
Each of these networks is distinct; however, the activities of
the CPNDS illustrate how the establishment of networks
may play an important role in the development of
personalised medicine. The CPNDS is an active surveil-
lance network that collects information on ADRs, and
operates predominantly within Canadian paediatric teaching
hospitals [9, 29]. The aim of the network is to improve drug
safety by identifying genetic markers that can predict which
patients are likely to experience specific serious ADRs, as
well as those who may experience decreased therapeutic
response to a drug. To help determine the role of genetic
variations in the development of ADRs, the network has
created a database of clinical ADRs and a bio-bank of DNA
and other samples. Among other examples, this approach
has already proven useful by contributing to the develop-
ment of a research protocol to validate reports of a potential
association between genetic variations in enzymes in the
CYP and UGT families in breastfeeding women taking
codeine and the development of codeine-induced central
nervous system (CNS) depression in their babies [30].
The development of databases containing information
about genomic positions and bio-banks containing tissue
samples from large numbers of individuals also make it
possible to conduct genome-wide association studies [19,
31]. Rather than selecting candidate genes, this type of
investigation can look at thousands of single nucleotide
polymorphisms across the genome in one investigation
which may represent an important approach for studying
complex, common diseases where multiple genetic varia-
tions may contribute to drug response.
As mentioned previously, despite the fact that many
biomarkers are currently available for use within the
clinical research setting, few have been integrated into
paediatric clinical practice. In addition, the validation
process of such markers in children remains an issue. As
a consequence, it is important to encourage the establish-
ment of paediatric bio-banks, as well as the connection of
existing bio-banks through intelligent informatics platforms
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in order to share data, integrate results and promote the use
of biomarkers in drug development and clinical trials.
Furthermore, the uptake of biomarkers within the drug
development process requires investment and research on
the part of the pharmaceutical industry. As of 2007, very
few pharmaceutical companies indicated ongoing pharma-
cogenomic or pharmacogenetic-related research in children
[20]. However, more recently an investigation performed
by Tufts suggests a growing interest and investment in this
area. Their report shows that 12%–50% of current clinical
pipelines of the companies interviewed involve personal-
ised medicines [32]. Thus, although at present paediatric
drug development and utilisation cannot benefit fully from
pharmacogenetic/pharmacogenomic findings there is hope
for the future. Further efforts are needed in order to reduce
the gap between promise and application.
Particular actions that have to be undertaken in order to
reduce the existing gaps include:
○ the identification of the most promising research
approaches for use in paediatric populations from
among those based on ‘omics’ sciences;
○ the development of model-based methodologies for
clinical trials in children based on the use of ‘omics’-
derived biomarkers;
○ the initiation and completion of pilot studies designed
with the goal of developing paediatric personalised
medicines in a specific sector such as oncology,
respiratory disease, neurodegenerative disease or
infective disease.
The development of personalised medicine is of rele-
vance for all paediatric patient groups, and in particular for
those populations that are generally deprived of drugs when
the traditional clinical trial approach is applied. Examples
of populations for whom the personalised medicine
approach will be particularly important are neonates and
children with rare diseases.
Choice of a model disease to study personalised
medicine in children: the need for personalised medicine
for children with rare neurological diseases
In the European Union (EU), a rare disease is defined as
one that affects fewer than five people per 10,000 [33].
Most of these conditions are genetically inherited and,
importantly, many develop during childhood. Although
individually uncommon, collectively there are thousands of
rare diseases, making them an important group of disorders
that affect a large number of patients throughout Europe. In
the context that we have so far identified somewhere in the
region of 5,000–8,000 distinct rare diseases, between 27
and 36 million people in the EU could be affected (6%–8%
of the population), making the management of these
conditions an important issue [33]. For these reasons, the
EU takes the position that rare diseases are a serious public
health concern and should be a priority in EU health and
research programmes.
Although neurodegenerative diseases are most prevalent
in the elderly, in rare cases they also affect individuals early
in life. In children, neurodegeneration leads to severe
mental retardation and premature death with devastating
consequences on their immediate environment. These
conditions also have relatively high costs for society. In
total, there are thought to be about 600 different genetically
inherited metabolic diseases, approximately 400 of which
involve the CNS with differing degrees of severity and rates
of degeneration. Lysosomal storage diseases (LSDs) are a
subgroup of approximately 40 of these metabolic disorders
that affect about one in 7,500 newborns [34, 35], although
more recently a combined incidence as high as one in 5,000
newborns has been suggested [36]. The proportion of
patients diagnosed with different LSDs in Australia
between 1980 and 1996 is shown in Fig. 1. These
conditions are caused by the lack of certain (lysosomal)
enzymes or lysosome components, thus preventing the
complete degradation of macromolecules and the recycling
of their components. As a result of the failure to degrade
these molecules, intermediate degradation products begin to
accumulate within the cells, affecting the function of
lysosomes and other cellular organelles. Each disorder is
named based on the type of protein molecules that
accumulate. The accumulation of these proteins starts
immediately after birth and continues throughout life, often
altering the structure and impairing the function of several
organs, including the CNS (Fig. 2). CNS pathology causes
mental retardation and progressive neurodegeneration
that ultimately ends in early death of these young patients
[37–41].
Our understanding of the pathogenesis of the LSDs has
grown dramatically over the last 10–20 years and there is
already a strong community supporting research and
scientific developments in this area, which includes
physicians, researchers, patient advocates and industry.
Thanks largely to advances in cellular and molecular
biology, and the incentives for drug development provided
by the introduction of the Orphan Drug Regulation in
Europe, we are now moving closer to being able to provide
therapies for neurological signs and symptoms in patients
with these conditions. The advanced state of knowledge of
the mechanisms of action of LSDs, in particular, is allowing
the elucidation of features of neurodegenerative diseases
that will most likely also prove to be useful in the study of
more prevalent neurodegenerative diseases that predomi-
nantly affect the elderly (e.g. Alzheimer’s and Parkinson’s
diseases). Furthermore, secondary events that lead to
234 EPMA Journal (2011) 2:231–239
Fig. 2 Impact of the accumulation of undegraded proteins in
lysosomal storage diseases. Images include brain scans showing:
a atrophy with enlarged Virchow–Robin spaces and ventricles,
b communicating hydrocephalus, and c spinal cord compression at
the cervical junctions. Other images show d corneal clouding, e larynx
thickening, f valvular alterations due to the accumulation of
undegraded substrates, and g–i dysostosis multiplex of back bone,
hand and long bones
Gaucher disease, 15%
MPS I (Hurler/Scheie),  8%
Metachromatic leukodystrophy, 7%
Sanfilippo disease type A, 7%
Fabry disease, 7%





Sanfilippo disease type B, 4%
Niemann–Pick disease type C, 4%
Cystinosis, 3%
Niemann–Pick disease type A/B, 3%
Mucolipidosis II/III, 2%
GM1 gangliosidosis, 2%
Sandhoff disease, 2% Other 6%
Fig. 1 Proportion of patients diagnosed with different lysosomal
storage diseases (LSDs) in Australia between 1980 and 1996. More
than ten patients were identified for 18 of the 27 LSDs diagnosed
during this period. Based on data from Meikle et al. [35]. MPS I,
mucopolysaccharidosis type I
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neurodegeneration (e.g. brain inflammation, alteration of
intracellular trafficking, impairment of autophagy, or
oxidative stress) are common to both paediatric and adult
neurodegenerative diseases (for a review see [40]) There-
fore, at least some of the observations relative to loss and
recovery of brain plasticity in paediatric neurodegeneration
can be extrapolated to adult disorders, and findings will
provide unique insights into the pathophysiology and
restorative capacities of neurodegenerative diseases in
general. In fact, suppressing the primary cause of neuro-
degeneration (e.g. by supplementing the missing enzyme)
in a young brain has the potential to maximise benefit as
the brain retains considerable plasticity at this stage of
development.
There are several factors that make the LSDs good
candidates for pharmacogenetic studies and personalised
medicine. The first is that the genetic basis of most of
these conditions is well defined; they are monogenic
disorders and many disease-causing mutations have
already been characterised. Although these mutations
are often private, they all result in reduced enzyme
levels and storage to varying degrees. Despite a current
general lack of awareness of these conditions among
physicians which can lead to delayed diagnosis, there is
the potential for pre-symptomatic diagnosis and, in many
cases, prenatal diagnosis [42–44]. This means that once
biomarkers that predict therapeutic response have been
identified, it will be possible to initiate the appropriate
treatment at an early stage of disease. Furthermore, for
many of the LSDs there is some overlap in the pathways
that are involved in the degradation of the proteins that
accumulate, making it likely that any biomarkers discov-
ered may apply in more than one condition. Another factor
is that patients show considerable phenotypic variability
(even those with the same underlying genetic mutation)
and there is similarly variation between individuals in
terms of response to therapy. At present, many different
therapeutic approaches have been proposed including
replacement of the missing enzyme (enzyme replacement
therapy, ERT), reduction of levels of the enzyme substrate
(substrate reduction therapy, SRT), the use of chemical
chaperones to stabilise existing but unstable enzyme
(chaperone therapy), bone marrow transplantation, and
gene therapies [45–47] (Fig. 3). Based on current
knowledge, predicting which patients will respond to
which treatment remains a challenge [48].
In order to make personalised medicine for children with
rare neurological disorders a reality it is necessary to refine
the techniques used to ensure that therapy gains access to
the CNS. Although it is known which enzyme deficiency
causes each of the LSDs, supplying a correct version of the
affected lysosomal enzyme intravenously only allows for
modification of the natural history of these diseases in the
peripheral organs (e.g. liver, spleen, joints, etc.). The
reason for this is that the therapeutic enzyme molecules
used in ERT are too large to cross the blood–brain-barrier
which protects the brain by allowing only those molecules
required naturally by the CNS to pass into the brain from
the peripheral circulation.
Proposed methods to circumvent the blood–brain-barrier
in patients with LSDs include the direct injection into the
brain of either the recombinant enzyme itself or of gene
transfer vehicles able to induce the synthesis of the enzyme
in genetically deficient brain cells [49]. Another approach is
to inhibit enzymes early in the biosynthetic pathway of the
accumulating protein(s) to reduce the number of molecules
that require degradation in the lysosome. Small pharma-
ceutical molecules that are capable of crossing the blood–
brain barrier are used to achieve this. In cases where the
affected lysosomal enzyme is present but does not function
because it is unstable, small pharmaceutical molecules
known as chemical chaperones that can cross the blood–
brain-barrier may be used to stabilise the enzyme, thus at
least partially restoring its function. As the process of
neurodegeneration observed in LSDs is characterised by
secondary events such as neuroinflammation, glutamatergic
activation and oxidative stress, the use of small molecules
with anti-inflammatory and/or neuroprotective properties
may also be a useful adjunctive approach to treat LSDs. To
date, the utility of most of these approaches has already
been demonstrated in animal models.
Looking to the future, there is also a need to establish
and validate biomarkers that will allow us to understand
both disease pathophysiology and which patients are most























Fig. 3 Routes of intervention for the treatment of patients with
lysosomal storage diseases
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Although we are currently able to quantify the stored
protein material and to assess changes in storage in
response to treatment, in general, these variables have not
proved to be reliable biomarkers for the LSDs. Other
candidate biomarkers are already under investigation. In the
future, the availability of biomarkers other than the stored
material, will allow the choice of the most appropriate
therapy (ERT, chaperone therapy or SRT) when taking into
account patient phenotype and expected disease severity
and course of progression. Once a therapy is developed that
can slow or prevent the progression of neurodegeneration,
it will become extremely important to facilitate early
detection of the genetic defect by newborn screening to
enable early intervention.
The development of new tools/technologies to diagnose
patients and to predict disease severity and progression, as
well as to assess new therapies, can be achieved only
through collaboration between existing stakeholders. The
first steps towards establishing a community to focus efforts
on developing therapies for rare neurological diseases of
childhood were taken in December 2010 at a meeting held
at the European Parliament in Brussels. This meeting,
which was organised by the Brains for Brain Foundation
[B4B (www.brains4brain.eu)], the European Brain Council
(EBC), the Lysosomal Storage Disease (LSD) Patient
Collaborative and the Veneto Region, and sponsored by
Member of the European Parliament, Mrs Amalia Sartori
(Veneto, Italy), brought together stakeholders from 13
EU countries, as well as the USA and Brazil. Those
registered for the meeting included 22 political represen-
tatives and members of 17 scientific organisations, 14
European family organisations, 10 biotechnology compa-
nies and over 40 European Universities. The organisers
called for a new initiative to coordinate the efforts of all
existing groups in Europe with the shared goal of
improving the treatment and care of patients with rare
neurological disorders. As commented in a recent
editorial, there is a need for harmonised interaction
between all stakeholders to enable the further develop-
ment of personalised medicine [50]. In line with this, the
present project will unite all interested parties, who are
working to increase the visibility, recognition and aware-
ness of rare neurological disorders in order to facilitate
early diagnosis of these conditions; to promote and
facilitate partnership and collaboration between physi-
cians, researchers, patient advocates, carers, policy- and
decision-makers and industry; to encourage and support
research and the translation of scientific breakthroughs
into clinical practice; to contribute to the establishment of
a standard of care for patients with rare neurological
disorders which is agreed across Europe; and to ensure
equity of access to diagnosis, treatment and care.
Concluding remarks and outlook
Achieving better and more predictable treatment outcomes
offers benefits in terms of reducing unnecessary treatment
and side effects and may ultimately lead to more cost–
effective healthcare. In order to progress the development
of personalised medicine it is necessary for these benefits to
be clearly demonstrated and for there to be buy-in and
investment from all stakeholders, including the pharmaceu-
tical industry, regulatory authorities and payers. The
increasing incorporation of biomarkers within product
pipelines is a sign of the growing interest of the
pharmaceutical industry in this area. Nevertheless, there is
still work to do in order to realise the potential of this
approach and there remains a need for more examples that
demonstrate proof of concept in clinical practice.
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